Beam Therapeutics posts wider than expected Q3 net loss as revenue drops

Overview

• US biotechnology firm reported wider-than-expected Q3 operating loss and net loss

• License and collaboration revenue declined sharply yr/yr

• Company ended Q3 with $1.0 bln in cash, expects runway into mid-2029

Outlook

• Beam expects to complete dosing in BEAM-302 pivotal cohort in first half of 2027

• US BLA submission for risto-cel in sickle cell disease expected as early as year-end 2026

• Dosing in BEAM-304 Phase 1/2 trial in PKU anticipated to initiate in early 2027

Result Drivers

• R&D SPENDING - Co reported marginally higher R&D expenses, reflecting continued investment in clinical and preclinical programs

• G&A COSTS - Higher G&A expenses contributed to increased net loss, as company builds commercial organization ahead of potential launches

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Beam Therapeutics Inc. is $44.00, about 70.1% above its November 2 closing price of $25.87

Reuters Recommended Reads

• Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

• Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

• Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)